CA2770680A1 - Procedes de detection de reponses a des therapies utilisant les niveaux de perforine - Google Patents

Procedes de detection de reponses a des therapies utilisant les niveaux de perforine Download PDF

Info

Publication number
CA2770680A1
CA2770680A1 CA2770680A CA2770680A CA2770680A1 CA 2770680 A1 CA2770680 A1 CA 2770680A1 CA 2770680 A CA2770680 A CA 2770680A CA 2770680 A CA2770680 A CA 2770680A CA 2770680 A1 CA2770680 A1 CA 2770680A1
Authority
CA
Canada
Prior art keywords
perforin
cells
sample
level
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2770680A
Other languages
English (en)
Inventor
Ramesh C. Nayak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSDX Inc
Original Assignee
MSDX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MSDX Inc filed Critical MSDX Inc
Publication of CA2770680A1 publication Critical patent/CA2770680A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2770680A 2009-08-10 2010-08-09 Procedes de detection de reponses a des therapies utilisant les niveaux de perforine Abandoned CA2770680A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23260509P 2009-08-10 2009-08-10
US61/232,605 2009-08-10
PCT/US2010/044921 WO2011019670A1 (fr) 2009-08-10 2010-08-09 Procédés de détection de réponses à des thérapies utilisant les niveaux de perforine

Publications (1)

Publication Number Publication Date
CA2770680A1 true CA2770680A1 (fr) 2011-02-17

Family

ID=43586421

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2770680A Abandoned CA2770680A1 (fr) 2009-08-10 2010-08-09 Procedes de detection de reponses a des therapies utilisant les niveaux de perforine

Country Status (3)

Country Link
EP (1) EP2464741A4 (fr)
CA (1) CA2770680A1 (fr)
WO (1) WO2011019670A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106885902B (zh) * 2017-03-03 2018-02-27 四川大学华西第二医院 以ncam‑1为检测指标的金标试剂盒及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7511121B2 (en) * 2001-03-09 2009-03-31 Arnason Barry G W Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors
CN1950512A (zh) * 2004-03-01 2007-04-18 彼得麦克凯勒姆肿瘤研究所 重组穿孔素、其表达和用途
EP2428216A3 (fr) * 2004-05-20 2012-05-23 ZymoGenetics, Inc. Procédés pour traiter le cancer au moyen d'IL-21 et une thérapie par anticorps monoclonaux
US8034613B2 (en) * 2005-06-01 2011-10-11 Wisconsin Alumni Research Foundation Multipotent lymphohematopoietic progenitor cells

Also Published As

Publication number Publication date
EP2464741A4 (fr) 2013-05-22
EP2464741A1 (fr) 2012-06-20
WO2011019670A1 (fr) 2011-02-17

Similar Documents

Publication Publication Date Title
Teleshova et al. Multiple sclerosis and optic neuritis: CCR5 and CXCR3 expressing T cells are augmented in blood and cerebrospinal fluid
CN108845129B (zh) 一种活动性结核类疾病的生物标志物的应用
Geraci et al. Differences in intercellular communication during clinical relapse and gadolinium-enhanced MRI in patients with relapsing remitting multiple sclerosis: a study of the composition of extracellular vesicles in cerebrospinal fluid
CN112526143B (zh) 髓系细胞触发受体2作为新型冠状病毒肺炎诊断或治疗靶点的应用
US9891213B2 (en) Granulocyte-based methods for detecting and monitoring immune system disorders
WO2013107826A2 (fr) Utilisation de l'expression de biomarqueurs cellulaires pour diagnostiquer le sepsis chez des patients bénéficiant de soins intensifs
EP4161951A1 (fr) Méthodes de détection et de traitement de patients atteints de covid nécessitant des soins intensifs
CA2770680A1 (fr) Procedes de detection de reponses a des therapies utilisant les niveaux de perforine
KR101926166B1 (ko) 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
US20110003304A1 (en) Method and kit for detection of autoimmune chronic urticaria
US20220042996A1 (en) Compositions and methods related to latrophilins as biomarkers for haematopoietic cell cancer
JP7175068B2 (ja) 癌治療に対する応答を予測するためのバイオマーカー
US20240019437A1 (en) Methods for the diagnosis and the treatment of graft-versus-host disease
Kimura et al. Th1‐CD11c+ B Cell Axis Associated with Response to Plasmapheresis in Multiple Sclerosis
Morsy et al. CD64 cell surface expression on neutrophils for diagnosis of neonatal sepsis
Ahmed et al. Regulatory T cell CD4‏ &CD25‏ expression and chemokine CXC ligand 13 level before and after corticosteroid therapy in pediatric ITP patients
US20230314411A1 (en) Methods and kits of assessing status, risk or prognosis of type 1 diabetes
Yang Zhou Identification of innate immune components as biomarkers of early liver inflammation
Zhou Identification of innate immune components as biomarkers of early liver inflammation
El Mahdaoui et al. Effects of anti-CD20 therapy on circulating and intrathecal follicular helper T cell subsets in multiple sclerosis
CN117295948A (zh) 淋巴细胞清除疗法后的继发性自身免疫的新型预测性生物标记物
Szerémy MDR—ABC Transporter Activity in Normal Population and in Rheumatoid Arthritis Patients: A Predictive Tool of Biological Therapeutic Response
WO2020115263A1 (fr) Utilisation de gilz en tant que biomarqueur dans la septicémie
Lehmann-Horn et al. ISNI 2012 Abstracts
Coalter et al. Autoimmune Encephalitis: Pathophysiology, Diagnosis and Treatment

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140811